activated marrow infiltrating lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01045460)
Timeline
Indications
Mechanism of action
- LymphocytesSupplementation
supplementation - lymphocytes
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- activated marrow infiltrating lymphocytes
- activated ptcy-mils
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04677361 | Early Phase 1 (Phase 1) | Oct 31, 2021 | Temple University, WindMIL Therapeutics |
| NCT02342613 | Phase 1 | Feb 1, 2015 | Johns Hopkins University |
| NCT01858558 | Phase 2 | Sep 1, 2013 | Johns Hopkins University, The Leukemia and Lymphoma Society |
| NCT01045460 | Phase 2 | Dec 1, 2009 | Johns Hopkins University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 3 | 3 | 2 | 2009 |
| Temple University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2013 |
| WindMIL Therapeutics | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1